Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer

CRC Clinical Trial

Official title:

A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01308086
• Other study ID #: CT/09.12
• Status: Active, not recruiting
• Phase: Phase 3
• First received: March 1, 2011
• Last updated: August 8, 2017
• Start date: October 2010
• Est. completion date: December 2017

Study information

• Verified date: August 2017
• Source: Hellenic Oncology Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare whether a 3-month treatment is at least not inferior to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs. 8 cycles) in terms of RFS in patients with high risk stage II or stage III radically resected colon cancer.

Description:

Six months of adjuvant chemotherapy with 5-FU and oxaliplatin for patients with stage III colon cancer is the world-wide standard of care, based on the MOSAIC and C-07 trials. However, it leads to significant cost, toxicity, and inconvenience. In particular, the onset of oxaliplatin induced cumulative dose-dependent neuropathies is a significant issue. The ability to maintain efficacy with a reduced duration of therapy would have clear advantage to patients, to providers, and to the health care system.

Multiple large trials in the 1990s demonstrated that the previous standard of 12 months of therapy could be reduced to 6 months. A single small trial with 5-FU alone demonstrated similar outcomes for 3 versus 6 months of therapy. Thus, it is proposed to definitively evaluate the non-inferiority of 3 months of oxaliplatin-based adjuvant chemotherapy versus the current standard of 6 months. The primary endpoint will be disease-free survival (DFS).

It is essential to have sufficient power to eliminate the possibility of clinically meaningful inferiority of 3 months of therapy: a huge number of patients will be necessary. Previous efforts and experience have conclusively demonstrated that in colon cancer, a single, global trial is impractical. Consequently, an international, prospective pooled analysis will be performed, gathering data of independent trials run in different countries, to answer the single primary hypothesis that 3 months of adjuvant therapy with FOLFOX/XELOX is non-inferior to the current standard of 6 months. Among six planned countries, the Greek intergroup will conduct one of these trials.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2000
• Est. completion date: December 2017
• Est. primary completion date: November 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically- - confirmed adenocarcinoma of the colon or rectum stage III or stage with at least one of the follow characteristics T4 tumours, undifferentiated tumor grade >3, bowel obstruction or perforation, vascular or lymphatic or perineural invasion, <12 nodes examined, Stage IV.

• Signed written informed consent

• Randomization between 2 -8 weeks after curative surgery

• Age >18 years

• ECOG performance Status 0-1

• Pretreatment CEA within UNL

• Post-menopausal women or women willing to accept the use of an effective contraception. Pre-menopausal women should have a negative pregnancy test within 72 hours prior to randomization

• Men should also accept to use an effective contraception

• R0 resections

Exclusion Criteria:

• Evidence of metastatic disease (including presence of tumor cells in ascites or peritoneal carcinomatosis resected "en bloc")

• Evidence of other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix)

• No pregnant or lactating women

• Presence of clinically relevant cardiovascular disease

• Presenc of medical history or current evidence of CNS disease

• Presence of peripheral neuropathy = grade 1 (CTCAE v. 3.0)

• History of clinically relevant psychiatric disability, precluding informed consent

Related Conditions & MeSH terms

• Colonic Neoplasms
• CRC

Intervention

Drug:
• 5-Fluorouracil
5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 12 cycles
• Leucovorin
Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 12 cycles
• Oxaliplatin
Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
• Capecitabine
Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
• Oxaliplatin
Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
• 5-Fluorouracil
5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 6 cycles
• Leucovorin
Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 6 cycles
• Capecitabine
Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
• Oxaliplatin
Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
• Oxaliplatin
Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles

Locations

Country	Name	City	State
Greece	University Hospital of Crete, Dep of Medical Oncology	Heraklion

Sponsors (2)

Lead Sponsor	Collaborator
Hellenic Oncology Research Group	University Hospital of Crete

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse Free Survival		3-years
Secondary	Overall Survival		3-years
Secondary	Safety Profil according to NCI-CTAE v 3.0	Percentage (%) of treatments delays and interaptions in each arm Percentage (%) of dose received versus planned dose in each arm	q2w